Device Trial Radar · NCT00462124
Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy
Last checked: Nov 20, 2026Latest source record: Aug 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jun 2007
Primary completion
Mar 2009
Study completion May 2009
Sponsor
- Lead sponsor
- BioProtectNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 18, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Male only, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Goal The study's primary goal is to assess the safety of the BioProtect biodegradable balloon implant and implantation procedure, in prostate cancer subjects undergoing routine XRT treatment. Safety of the BioProtect device will be assessed by reporting adverse events. Secondary Goal The study's secondary goal is to evaluate the effectiveness of the BioProtect biodegradable balloon implant in prostate cancer subjects undergoing routine XRT treatment. Effectiveness will be assessed in terms of increased distance between anterior rectal wall and prostate and noticeable reduction of isodose to the rectum.
Conditions
- Prostate Cancer
Interventions
Absorbable perirectal spacerDevice
biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Balloon ImplantTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ichilov Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.